

HOUSE BILL 674

E4, J1

0lr0100

By: **Chair, Judiciary Committee (By Request – Departmental – Health)**

Introduced and read first time: January 29, 2020

Assigned to: Judiciary

Committee Report: Favorable

House action: Adopted

Read second time: March 8, 2020

CHAPTER _____

1 AN ACT concerning

2 **Controlled Dangerous Substances – Schedules**

3 FOR the purpose of altering the lists of substances designated as controlled dangerous
4 substances under certain schedules under the Maryland Controlled Dangerous
5 Substances Act; making stylistic changes; and generally relating to schedules for
6 controlled dangerous substances.

7 BY repealing and reenacting, with amendments,
8 Article – Criminal Law
9 Section 5–402 through 5–406
10 Annotated Code of Maryland
11 (2012 Replacement Volume and 2019 Supplement)

12 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
13 That the Laws of Maryland read as follows:

14 **Article – Criminal Law**

15 5–402.

16 (a) Schedule I consists of each controlled dangerous substance:

17 (1) listed in this section;

18 (2) added to Schedule I by the Department under § 5–202(b) of this title; or

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

Underlining indicates amendments to bill.

~~Strike out~~ indicates matter stricken from the bill by amendment or deleted from the law by amendment.



1 (3) designated as a Schedule I controlled dangerous substance by the
2 federal government unless the Department objects under § 5–202(f) of this title.

3 (b) Unless specifically excepted under this subtitle or listed in another schedule,
4 any of the following opiates, including their isomers, including optical and geometric
5 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the
6 existence of such isomers, esters, ethers, or salts is possible within the specific chemical
7 designation, are substances listed in Schedule I:

8 (1) [acetyl–alpha–methylfentanyl] ACETYL–ALPHA–METHYLFENTANYL
9 (*N*–[1–(1–METHYL–2–PHENETHYL)–4–PIPERIDINYL]–*N*–PHENYLACETAMIDE);

10 (2) acetylmethadol;

11 (3) [acetyl fentanyl
12 (*n*–(1–phenethylpiperidine–4–yl)–*n*–phenylacetamide)] ACETYL FENTANYL
13 (*N*–(1–PHENETHYLPiPERIDIN–4–YL)–*N*–PHENYLACETAMIDE);

14 (4) ACRYL FENTANYL
15 (*N*–(1–PHENETHYLPiPERIDIN–4–YL)–*N*–PHENYLACRYLAMIDE);

16 (5) [ah–7921 AH–7921
17 (3,4–dichloro–*n*–[(1–dimethylamino)cyclohexylmethyl])benzamide] AH–7921
18 (3,4–DICHLORO–*N*–[(1–DIMETHYLAMINO) CYCLOHEXYLMETHYL]) BENZAMIDE;

19 [(5)] (6) allylprodine;

20 [(6)] (7) alphacetylmethadol, except [levoalphacetylmethadol]
21 LEVO–ALPHACETYLMETHADOL;

22 [(7)] (8) alphameprodine;

23 [(8)] (9) alphamethadol;

24 [(9)] (10) [alpha–methylfentanyl] ALPHA–METHYLFENTANYL
25 (*N*–[1–(ALPHA–METHYL–BETA–PHENYL)ETHYL–4–PIPERIDYL] PROPIONANILIDE;
26 1–(1–METHYL–2–PHENYLETHYL)–4–(*N*–PROPANILIDO) PIPERIDINE);

27 [(10)] (11) [alpha–methylthiofentanyl] ALPHA–METHYLTHIOFENTANYL
28 (*N*–[1–METHYL–2–(2–THIENYL)ETHYL–4–PIPERIDINYL]–*N*–
29 PHENYLPROPANAMIDE);

30 [(11)] (12) benzethidine;

1 [(12)] (13) betacetylmethadol;

2 [(13)] (14) [beta-hydroxyfentanyl] BETA-HYDROXYFENTANYL
3 (N-[1-(2-HYDROXY-2-PHENETHYL)-4-PIPERIDINYL]-N-PHENYLPROPANAMIDE);

4 [(14)] (15) beta-hydroxy-3-methylfentanyl;

5 (16) N-[1-[2-HYDROXY-2-(THIOPHEN-2-YL)ETHYL]PIPERIDIN-4-
6 YL]-N-PHENYLPROPIONAMIDE;

7 [(15)] (17) betameprodine;

8 [(16)] (18) betamethadol;

9 [(17)] (19) betaprodine;

10 (20) BUTYRYL FENTANYL
11 (N-(1-PHENETHYLPIPERIDIN-4-YL)-N-PHENYLBUTYRAMIDE);

12 [(18)] (21) clonitazene;

13 [(19)] (22) dextromoramide;

14 [(20)] (23) diampromide;

15 [(21)] (24) diethylthiambutene;

16 [(22)] (25) difenoxin;

17 [(23)] (26) dimenoxadol;

18 [(24)] (27) dimepheptanol;

19 [(25)] (28) dimethylthiambutene;

20 [(26)] (29) dioxaphetyl butyrate;

21 [(27)] (30) dipipanone;

22 [(28)] (31) ethylmethylthiambutene;

23 [(29)] (32) etonitazene;

24 [(30)] (33) etoxeridine;

- 1 (5) codeine–N–oxide;
- 2 (6) cyprenorphine;
- 3 (7) desomorphine;
- 4 (8) dihydromorphine;
- 5 (9) drotebanol;
- 6 (10) etorphine (except hydrochloride salt);
- 7 (11) heroin;
- 8 (12) hydromorphinol;
- 9 (13) methyldesorphine;
- 10 (14) methyldihydromorphine;
- 11 (15) morphine methylbromide;
- 12 (16) morphine methylsulfonate;
- 13 (17) morphine–N–oxide;
- 14 (18) myrophine;
- 15 (19) nicocodeine;
- 16 (20) nicomorphine;
- 17 (21) normorphine;
- 18 (22) pholcodine; and
- 19 (23) thebacon.

20 (d) Unless specifically excepted under this subtitle or listed in another schedule,
21 any material, compound, mixture, or preparation that contains any quantity of the
22 following hallucinogenic substances, or that contains any of its salts, isomers, including
23 optical, position, and geometric isomers, or salts of isomers, whenever the existence of such
24 salts, isomers, or salts of isomers is possible within the specific chemical designation, is a
25 substance listed in Schedule I:

- 26 (1) alpha–ethyltryptamine;

- 1 (2) 4-bromo-2,5-dimethoxy-amphetamine;
- 2 (3) 4-bromo-2,5-dimethoxyphenethylamine;
- 3 (4) 2,5-dimethoxyamphetamine;
- 4 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- 5 (6) [2,5-dimethoxy-4-(n)-propylthiophenethylamine (2c-t-7)]
- 6 **2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE (2C-T-7);**
- 7 (7) 4-methoxyamphetamine (PMA);
- 8 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 9 (9) 4-methyl-2,5-dimethoxy-amphetamine;
- 10 (10) 3,4-methylenedioxy amphetamine;
- 11 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 12 (12) [3,4-methylenedioxy-n-ethylamphetamine]
- 13 **3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDA);**
- 14 (13) [n-hydroxy-3,4-methylenedioxyamphetamine]
- 15 **N-HYDROXY-3,4-METHYLENEDIOXYAMPHETAMINE;**
- 16 (14) 3,4,5-trimethoxyamphetamine;
- 17 (15) [5-methoxy-n, n-dimethyltryptamine]
- 18 **5-METHOXY-N, N-DIMETHYLTRYPTAMINE;**
- 19 (16) alpha-methyltryptamine (AMT);
- 20 (17) bufotenine;
- 21 (18) diethyltryptamine (DET);
- 22 (19) dimethyltryptamine (DMT);
- 23 (20) [5-methoxy-n, n-diisopropyltryptamine (5-MEO-DIPT)]
- 24 **5-METHOXY-N, N-DIISOPROPYLTRYPTAMINE (5-MEO-DIPT);**
- 25 (21) ibogaine;
- 26 (22) lysergic acid diethylamide;

- 1 (23) marijuana;
- 2 (24) mescaline;
- 3 (25) [parahexyl] **PARAHEXYL-7374**;
- 4 (26) peyote (meaning all parts of the plant presently classified botanically
5 as *Lophophora williamsii* lemaire, whether growing or not, the seeds thereof, any extract
6 from any part of such plant, and every compound, manufacture, salt, derivative, mixture,
7 or preparation of such plant, its seeds, or extracts);
- 8 (27) [n-ethyl-3-piperidyl benzilate] **N-ETHYL-3-PIPERIDYL**
9 **BENZILATE**;
- 10 (28) [n-methyl-3-piperidyl benzilate] **N-METHYL-3-PIPERIDYL**
11 **BENZILATE**;
- 12 (29) psilocybin;
- 13 (30) psilocyn;
- 14 (31) tetrahydrocannabinols;
- 15 (32) ethylamine analog of phencyclidine
16 (N-ethyl-1-phenylcyclohexylamine);
- 17 (33) pyrrolidine analog of phencyclidine
18 (1-(1-phenylcyclohexyl)-pyrrolidine);
- 19 (34) [thiophene analog of phencyclidine
20 (1-(1-(2-thienyl)-cyclohexyl)-piperidine)] **THIOPHENE ANALOG OF PHENCYCLIDINE**
21 **(1-[1-(2-THIENYL)-CYCLOHEXYL]-PIPERIDINE)**;
- 22 (35) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
- 23 (36) **4-METHYLMETHCATHINONE (MEPHEDRONE)**;
- 24 **(37)** 3, 4-methylenedioxypropylvalerone (MDPV);
- 25 [(37) 4-methylmethcathinone (mephedrone);
- 26 (38) 4-methoxymethcathinone (methedrone);]
- 27 [(39) **(38)** [2-(2,5-dimethoxy-4-ethylphenyl) ethanamine (2c-e)]
28 **2-(2,5-DIMETHOXY-4-ETHYLPHENYL) ETHANAMINE (2C-E)**;

1 [(40)] (39) [2-(2,5-dimethoxy-4-methylphenyl) ethanamine (2c-d)]
 2 **2-(2,5-DIMETHOXY-4-METHYLPHENYL) ETHANAMINE (2C-D);**

3 [(41)] (40) [2-(4-chloro-2,5-dimethoxyphenyl) ethanamine (2c-c)]
 4 **2-(4-CHLORO-2,5-DIMETHOXYPHENYL) ETHANAMINE (2C-C);**

5 [(42)] (41) [2-(4-iodo-2,5-dimethoxyphenyl) ethanamine (2c-i)]
 6 **2-(4-IODO-2,5-DIMETHOXYPHENYL) ETHANAMINE (2C-I);**

7 [(43)] (42) [2-(4-ethylthio-2,5-dimethoxyphenyl) ethanamine (2c-t-2)]
 8 **2-[4-(ETHYLTHIO)-2,5-DIMETHOXYPHENYL] ETHANAMINE (2C-T-2);**

9 [(44)] (43) [2-(4-isopropylthio)-2,5-dimethoxyphenyl] ethanamine
 10 (2c-t-4) **2-[4-(ISOPROPYLTHIO)-2,5-DIMETHOXYPHENYL] ETHANAMINE (2C-T-4);**

11 [(45)] (44) [2-(2,5-dimethoxyphenyl) ethanamine (2c-h)]
 12 **2-(2,5-DIMETHOXYPHENYL) ETHANAMINE (2C-H);**

13 (45) **2-(2,5-DIMETHOXY-4-NITRO-PHENYL) ETHANAMINE (2C-N);**

14 (46) [2-(2,5-dimethoxy-4-(n)-propylphenyl) ethanamine (2c-p)]
 15 **2-(2,5-DIMETHOXY-4-(N)-PROPYLPHENYL) ETHANAMINE (2C-P);**

16 (47) [3,4-methylenedioxy-methcathinone (methylone)]
 17 **3,4-METHYLENEDIOXY-N-METHYLCATHINONE (METHYLONE);**

18 (48) [(1-pentyl-1h-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl)
 19 methanone (ur-144)] **(1-PENTYL-1H-INDOL-3-YL)**
 20 **(2,2,3,3-TETRAMETHYLCYCLOPROPYL) METHANONE (UR-144);**

21 (49) [[1-(5-fluoro-pentyl)-1h-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)
 22 methanone (5-fluoro-ur-144, xlr11)]
 23 **[1-(5-FLUORO-PENTYL)-1H-INDOL-3-YL](2,2,3,3-TETRAMETHYLCYCLOPROPYL)**
 24 **METHANONE (5-FLUORO-UR-144, XLR11);**

25 (50) [n-(1-adamantyl)-1-pentyl-1h-indazole-3-carboxamide (apinaca,
 26 akb48)] **N-(1-ADAMANTYL)-1-PENTYL-1H-INDAZOLE-3-CARBOXAMIDE**
 27 **(APINACA, AKB48);**

28 (51) [quinolin-8-yl 1-pentyl-1h-indole-3-carboxylate (pb-22)]
 29 **QUINOLIN-8-YL 1-PENTYL-1H-INDOLE-3-CARBOXYLATE (PB-22);**

30 (52) [quinolin-8-yl 1-(5-fluoropentyl)-1h-indole-3-carboxylate

- 1 (5-fluoro-pb-22)] QUINOLIN-8-YL
 2 **1-(5-FLUOROPENTYL)-1H-INDOLE-3-CARBOXYLATE (5-FLUORO-PB-22);**
- 3 (53)
 4 [n-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1h-indazole-3-
 5 carboxamide (ab-fubinaca)]
 6 **N-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)-1-(4-FLUOROBENZYL)-1H-**
 7 **INDAZOLE-3-CARBOXAMIDE (AB-FUBINACA);**
- 8 (54) [n-(1-amino-3,
 9 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1h-indazole-3-carboxamide (adb-pinaca)]
 10 **N-(1-AMINO-3,**
 11 **3-DIMETHYL-1-OXOBUTAN-2-YL)-1-PENTYL-1H-INDAZOLE-3-CARBOXAMIDE**
 12 **(ADB-PINACA);**
- 13 (55) [2-(4-iodo-2,5-dimethoxyphenyl)-n-(2-methoxybenzyl) ethanamine
 14 (25I-nbome)] **2-(4-iodo-2,5-DIMETHOXYPHENYL)-N-(2-METHOXYBENZYL)**
 15 **ETHANAMINE (25I-NBOME);**
- 16 (56) [2-(4-chloro-2,5-dimethoxyphenyl)-n-(2-methoxybenzyl)
 17 ethanamine (25C-nbome)]
 18 **2-(4-CHLORO-2,5-DIMETHOXYPHENYL)-N-(2-METHOXYBENZYL) ETHANAMINE**
 19 **(25C-NBOME);**
- 20 (57) [2-(4-bromo-2,5-dimethoxyphenyl)-n-(2-methoxybenzyl)
 21 ethanamine (25B-nbome)]
 22 **2-(4-BROMO-2,5-DIMETHOXYPHENYL)-N-(2-METHOXYBENZYL) ETHANAMINE**
 23 **(25B-NBOME);**
- 24 (58) marijuana extract (meaning an extract containing one or more
 25 cannabinoids that has been derived from any plant of the genus cannabis, other than the
 26 separated resin, whether crude or purified, obtained from the plant);
- 27 (59) [4-methyl-n-ethylcathinone (4-MEC)]
 28 **4-METHYL-N-ETHYLCATHINONE (4-MEC);**
- 29 (60) [4-methyl-alpha-pyrrolidinopropiophenone (4-MEPPP)]
 30 **4-METHYL-ALPHA-PYRROLIDINOPROPIOPHENONE (4-MEPPP);**
- 31 (61) [alpha-pyrrolidinopentiophenone (A-PVP)]
 32 **ALPHA-PYRROLIDINOPENTIOPHENONE (ALPHA-PVP);**
- 33 (62) 1-(1,3-benzodioxol-5-yl)-2-(methylamino) butan-1-one (butylone);
- 34 (63) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);

1 (64) 1-(1,3-benzodioxol-5-yl)-2-(methylamino) pentan-1-one (pentylone);

2 (65) [4-fluoro-n-methylcathinone (flephedrone)]
 3 **4-FLUORO-N-METHYLCATHINONE (FLEPHEDRONE);**

4 (66) [3-fluoro-n-methylcathinone (3-FMC)]
 5 **3-FLUORO-N-METHYLCATHINONE (3-FMC);**

6 (67) [cannabimimetic agents;

7 (68)] 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone);
 8 [and]

9 [(69)] **(68)** [alpha-pyrrolidinobutiophenone (A-PBP)]
 10 **ALPHA-PYRROLIDINOBUTIOPHENONE (ALPHA-PBP);**

11 **(69)** *N*-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)-1-
 12 **(CYCLOHEXYLMETHYL)-1H-INDAZOLE-3-CARBOXAMIDE (AB-CHMINACA);**

13 **(70)** *N*-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)-1-PENTYL-1H-
 14 **INDAZOLE-3-CARBOXAMIDE (AB-PINACA);**

15 **(71)** [1-(5-FLUOROPENTYL)-1H-INDAZOL-3-YL](NAPHTHALEN-1-
 16 **YL)METHANONE (THJ-2201); AND**

17 **(72)** *N*-(1-AMINO-3,3-DIMETHYL-1-OXOBUTAN-2-YL)-1-
 18 **(CYCLOHEXYLMETHYL)-1H-INDAZOLE-3-CARBOXAMIDE (MAB-CHMINACA).**

19 [(e) Unless specifically excepted under this subtitle or listed in another schedule,
 20 any material, compound, mixture, or preparation that contains any quantity of the
 21 following substances, or that contains their salts, isomers, or salts of isomers, whenever the
 22 existence of such salts, isomers, or salts of isomers is possible within the specific chemical
 23 designation, is a substance listed in Schedule I:

24 (1) 5-(1, 1-dimethylheptyl)-2-[(1r,3s)-3-hydroxycyclohexyl]-phenol
 25 (cp-47,497);

26 (2) 5-(1,1-dimethyloctyl)-2-[(1r,3s)3-hydroxycyclohexyl]-phenol
 27 (cp-47,497 c8 homologue);

28 (3) 1-pentyl-3-(1-naphthoyl) indole (JWH-018 and AM678)

29 (4) 1-butyl-3-(1-naphthoyl) indole (JWH-073);

- 1 (5) 1-hexyl-3-(1-naphthoyl) indole (JWH-019);
- 2 (6) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl) indole (JWH-200);
- 3 (7) 1-pentyl-3-(2-methoxyphenylacetyl) indole (JWH-250);
- 4 (8) 1-pentyl-3-(1-(4-methoxynaphthoyl) indole (JWH-081);
- 5 (9) 1-pentyl-3-(4-methyl-1-naphthoyl) indole (JWH-122);
- 6 (10) 1-pentyl-3-(4-chloro-1-naphthoyl) indole (JWH-398);
- 7 (11) 1-(5-fluoropentyl)-3-(1-naphthoyl) indole (AM2201);
- 8 (12) 1-(5-fluoropentyl)-3-(2-iodobenzoyl) indole (AM694);
- 9 (13) 1-pentyl-3-[(4-methoxy)-benzoyl] indole (SR-19 and RCS-4);
- 10 (14) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl) indole (SR-18 and
11 RCS-8); and
- 12 (15) 1-pentyl-3-(2-chlorophenylacetyl) indole (JWH-203).]

13 [(f) (E) Unless specifically excepted under this subtitle or listed in another
14 schedule, a material, compound, mixture, or preparation that contains any quantity of the
15 following substances having depressant effects on the central nervous system, or that
16 contains its salts, isomers, or salts of isomers, whenever the existence of such salts, isomers,
17 or salts of isomers is possible within the specific chemical designation, is a substance listed
18 in Schedule I:

- 19 (1) [mecloqualone;
- 20 (2) methaqualone; and
- 21 (3)] gamma-hydroxybutyric acid **(GHB)**;
- 22 **(2) MECLOQUALONE; AND**
- 23 **(3) METHAQUALONE.**

24 [(g) (F) Unless specifically excepted or listed in another schedule, any material,
25 compound, mixture, or preparation that contains any quantity of the following substances
26 having a stimulant effect on the central nervous system, or that contains its salts, isomers,
27 or salts of isomers, is a substance listed in Schedule I:

- 28 (1) aminorex;

- 1 (2) [n-benzylpiperazine] **N-BENZYLPIPERAZINE (BZP)**;
- 2 (3) cathinone;
- 3 (4) fenethylamine;
- 4 (5) methcathinone;
- 5 (6) [4-methylaminorex];
- 6 (7) (±)CIS-4-methylaminorex] (±)CIS-4-METHYLAMINOREX
 7 ((±)CIS-4,5-DIHYDRO-4-METHYL-5-PHENYL-2-OXAZOLAMINE);
- 8 [(8) (7) [n-ethylamphetamine] **N-ETHYLAMPHETAMINE**; and
- 9 [(9) (8) [n, n-dimethylamphetamine] **N,**
 10 **N-DIMETHYLAMPHETAMINE**.

11 (G) UNLESS SPECIFICALLY EXCEPTED UNDER THIS SUBTITLE OR LISTED IN
 12 ANOTHER SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION
 13 THAT CONTAINS ANY QUANTITY OF THE FOLLOWING SUBSTANCES, OR THAT
 14 CONTAINS THEIR SALTS, ISOMERS, OR SALTS OF ISOMERS, WHENEVER THE
 15 EXISTENCE OF SUCH SALTS, ISOMERS, OR SALTS OF ISOMERS IS POSSIBLE WITHIN
 16 THE SPECIFIC CHEMICAL DESIGNATION, IS A SUBSTANCE LISTED IN SCHEDULE I:

- 17 (1) 5-(1, 1-DIMETHYLHEPTYL)-2-[(1R,3S)-3-
 18 HYDROXYCYCLOHEXYL]-PHENOL (CP-47,497);
- 19 (2) 5-(1,1-DIMETHYLOCTYL)-2-[(1R,3S)-3-
 20 HYDROXYCYCLOHEXYL]-PHENOL (CP-47,497 C8 HOMOLOG);
- 21 (3) 1-PENTYL-3-(1-NAPHTHOYL) INDOLE (JWH-018 AND AM678);
- 22 (4) 1-BUTYL-3-(1-NAPHTHOYL) INDOLE (JWH-073);
- 23 (5) 1-HEXYL-3-(1-NAPHTHOYL) INDOLE (JWH-019);
- 24 (6) 1-[2-(4-MORPHOLINYL)ETHYL]-3-(1-NAPHTHOYL) INDOLE
 25 (JWH-200);
- 26 (7) 1-PENTYL-3-(2-METHOXYPHENYLACETYL) INDOLE (JWH-250);
- 27 (8) 1-PENTYL-3-[1-(4-METHOXYNAPHTHOYL)] INDOLE (JWH-081);

- 1 **(9) 1-PENTYL-3-(4-METHYL-1-NAPHTHOYL) INDOLE (JWH-122);**
2 **(10) 1-PENTYL-3-(4-CHLORO-1-NAPHTHOYL) INDOLE (JWH-398);**
3 **(11) 1-(5-FLUOROPENTYL)-3-(1-NAPHTHOYL) INDOLE (AM2201);**
4 **(12) 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL) INDOLE (AM694);**
5 **(13) 1-PENTYL-3-[(4-METHOXY)-BENZOYL] INDOLE (SR-19 AND**
6 **RCS-4);**
7 **(14) 1-CYCLOHEXYLETHYL-3-(2-METHOXYPHENYLACETYL) INDOLE**
8 **7008 (SR-18 AND RCS-8); AND**
9 **(15) 1-PENTYL-3-(2-CHLOROPHENYLACETYL) INDOLE (JWH-203).**

10 (h) (1) In this subsection:

- 11 (i) “controlled dangerous substance analogue” means a substance:
12 1. that has a chemical structure substantially similar to the
13 chemical structure of a controlled dangerous substance listed in Schedule I or Schedule II;
14 and
15 2. that has a stimulant, depressant, or hallucinogenic effect
16 on the central nervous system that is substantially similar to or greater than the stimulant,
17 depressant, or hallucinogenic effect on the central nervous system of a controlled dangerous
18 substance listed in Schedule I or Schedule II; but

19 (ii) “controlled dangerous substance analogue” does not include:

- 20 1. a controlled dangerous substance;
21 2. a substance for which there is an approved new drug
22 application; or
23 3. a substance exempted for investigational use under § 506
24 of the Federal Food, Drug, and Cosmetic Act.

25 (2) To the extent intended for human consumption, each controlled
26 dangerous substance analogue is a substance listed in Schedule I.

27 (i) The Department may not add a substance to Schedule I under § 5-202 of this
28 title unless the Department finds:

- 1 (1) a high potential for abuse of the substance;
- 2 (2) no accepted medical use in the United States for the substance; and
- 3 (3) a lack of accepted safety for use of the substance under medical
4 supervision.
- 5 5–403.

6 (a) Schedule II consists of each controlled dangerous substance:

- 7 (1) listed in this section;
- 8 (2) added to Schedule II by the Department under § 5–202(b) of this title;
9 or
- 10 (3) designated as a Schedule II controlled dangerous substance by the
11 federal government unless the Department objects under § 5–202(f) of this title.

12 (b) **UNLESS SPECIFICALLY EXCEPTED OR UNLESS LISTED IN ANOTHER**
13 **SCHEDULE, ANY OF THE FOLLOWING SUBSTANCES WHETHER PRODUCED DIRECTLY**
14 **OR INDIRECTLY BY EXTRACTION FROM SUBSTANCES OF VEGETABLE ORIGIN, OR**
15 **INDEPENDENTLY BY MEANS OF CHEMICAL SYNTHESIS, OR BY A COMBINATION OF**
16 **EXTRACTION AND CHEMICAL SYNTHESIS:**

17 (1) [Unless the substance is listed in another schedule and except as
18 provided in paragraph (2) of this subsection, opium and opiate, and a salt, compound,
19 derivative, or preparation of opium or opiate is a substance listed in Schedule II, including]
20 **OPIUM AND OPIATE, AND ANY SALT, COMPOUND, DERIVATIVE, OR PREPARATION OF**
21 **OPIUM OR OPIATE EXCLUDING APOMORPHINE, THEBAINE–DERIVED BUTORPHANOL,**
22 **DEXTRORPHAN, NALBUPHINE, NALDEMEDINE, NALMEFENE, NALOXEGOL,**
23 **NALOXONE, AND NALTREXONE, AND THEIR RESPECTIVE SALTS, BUT INCLUDING THE**
24 **FOLLOWING:**

- 25 (i) [raw opium] **CODEINE;**
- 26 (ii) [opium extracts] **DIHYDROETORPHINE;**
- 27 (iii) [opium fluid extract] **ETHYLMORPHINE;**
- 28 (iv) [opium fluid] **ETORPHINE HYDROCHLORIDE;**
- 29 (v) [powdered] **GRANULATED** opium;
- 30 (vi) [granulated opium] **HYDROCODONE;**

- 1 (vii) [tincture of opium] **HYDROMORPHONE**;
- 2 (viii) [codeine] **METOPON**;
- 3 (ix) [dextropropoxyhene bulk (nondosage form)] **MORPHINE**;
- 4 (x) [dihydroetorphine] **OPIUM EXTRACTS**;
- 5 (xi) [ethylmorphine] **OPIUM FLUID**;
- 6 (xii) [etorphine hydrochloride] **ORIPAVINE**;
- 7 (xiii) [hydrocodone] **OXYCODONE**;
- 8 (xiv) [hydromorphone] **OXYMORPHONE**;
- 9 (xv) [metopon] **POWDERED OPIUM**;
- 10 (xvi) [morphine] **RAW OPIUM**;
- 11 (xvii) [oripavine] **THEBAINE**; AND
- 12 (xviii) [oxycodone;
- 13 (xix) oxymorphone; and
- 14 (xx) thebaine.] **TINCTURE OF OPIUM**;

15 [(2) Apomorphine, dextrorphan, nalbuphine, naloxone, and naltrexone, and
16 their respective salts, are not substances listed in Schedule II.]

17 **(2) ANY SALT, COMPOUND, DERIVATIVE, OR PREPARATION THEREOF**
18 **WHICH IS CHEMICALLY EQUIVALENT OR IDENTICAL WITH ANY OF THE SUBSTANCES**
19 **REFERRED TO IN ITEM (1) OF THIS SUBSECTION, EXCEPT THAT THESE SUBSTANCES**
20 **MAY NOT INCLUDE THE ISOQUINOLINE ALKALOIDS OF OPIUM;**

21 [(3) Substances listed in Schedule II also include:

22 (i) except for the isoquinoline alkaloids of opium, a salt, compound,
23 derivative, or preparation that is chemically equivalent or identical to a substance listed in
24 paragraph (1) of this subsection;]

25 [(ii) **(3) opium poppy[, AND poppy straw[, and poppy straw**
26 **concentrate];**

1 ~~[(iii)]~~ **(4)** coca [leaf] LEAVES AND ANY SALT, COMPOUND,
2 DERIVATIVE, OR PREPARATION OF COCA LEAVES, INCLUDING COCAINE AND
3 ECGONINE AND THEIR SALTS, ISOMERS, DERIVATIVES AND SALTS OF ISOMERS AND
4 DERIVATIVES, AND ANY SALT, COMPOUND, DERIVATIVE, OR PREPARATION THEREOF
5 WHICH IS CHEMICALLY EQUIVALENT OR IDENTICAL WITH ANY OF THESE
6 SUBSTANCES, EXCEPT THAT THE SUBSTANCES MAY NOT INCLUDE:

7 **(I)** DECOCAINIZED COCA LEAVES OR EXTRACTION OF
8 COCA LEAVES, WHICH EXTRACTIONS DO NOT CONTAIN COCAINE OR ECGONINE; OR

9 **(II)** [¹²³I]IOFLUPANE; AND

10 [(iv) cocaine, its salts, optical and geometric isomers, and salts of
11 isomers;

12 (v) ecgonine, its derivatives, their salts, isomers, and salts of
13 isomers; and

14 (vi) a compound, mixture, or preparation that contains any of the
15 substances listed in this section.

16 (4) A substance that is listed in Schedule II is included whether produced:

17 (i) directly or indirectly by extraction from substances of vegetable
18 origin;

19 (ii) independently by chemical synthesis; or

20 (iii) by a combination of extraction and chemical synthesis]

21 **(5)** CONCENTRATE OF POPPY STRAW (THE CRUDE EXTRACT OF POPPY
22 STRAW IN EITHER LIQUID, SOLID, OR POWDER FORM WHICH CONTAINS THE
23 PHENANTHRENE ALKALOIDS OF THE OPIUM POPPY).

24 (c) [(1) These opiates are substances listed in Schedule II] UNLESS
25 SPECIFICALLY EXCEPTED OR UNLESS IN ANOTHER SCHEDULE ANY OF THE
26 FOLLOWING OPIATES, INCLUDING ITS ISOMERS, ESTERS, ETHERS, SALTS, AND SALTS
27 OF ISOMERS, ESTERS, AND ETHERS WHENEVER THE EXISTENCE OF SUCH ISOMERS,
28 ESTERS, ETHERS, AND SALTS IS POSSIBLE WITHIN THE SPECIFIC CHEMICAL
29 DESIGNATION, DEXTRORPHAN AND LEVOPROPOXYPHENE EXCEPTED:

30 [(i)] **(1)** alfentanil;

31 [(ii)] **(2)** alphaprodine;

- 1 [(iii) (3) anileridine;
- 2 [(iv) (4) bezitramide;
- 3 [(v) (5) BULK DEXTROPROPOXYPHENE (NON-DOSAGE
4 **FORMS);**
- 5 (6) carfentanil;
- 6 [(vi) (7) dihydrocodeine;
- 7 [(vii) (8) diphenoxylate;
- 8 [(viii) dronabinol (in oral solution);]
- 9 [(ix) (9) fentanyl;
- 10 [(x) (10) isomethadone;
- 11 [(xi) (11) [levoalphacetylmethadol]
12 **LEVO-ALPHACETYLMETHADOL;**
- 13 [(xii) (12) levomethorphan;
- 14 [(xiii) (13) levorphanol;
- 15 [(xiv) (14) metazocine;
- 16 [(xv) (15) methadone;
- 17 [(xvi) (16) methadone – intermediate, 4-cyano-2-dimethylamino-4,
18 4-diphenyl butane;
- 19 [(xvii) (17) [moramide – intermediate, 2-methyl-3- morpholino-1,
20 1-diphenyl-propene-carboxylic acid] MORAMIDE – INTERMEDIATE,
21 **2-METHYL-3- MORPHOLINO-1, 1-DIPHENYLPROPANE-CARBOXYLIC ACID;**
- 22 [(xviii) (18) pethidine (**MEPERIDINE**);
- 23 [(xix) (19) pethidine – intermediate – A,
24 4-cyano-1-methyl-4-phenylpiperidine;
- 25 [(xx) (20) pethidine – intermediate – B,
26 ethyl-4-phenylpiperidine-4-carboxylate;

- 1 [(xxi)] **(21)** pethidine – intermediate – C,
 2 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 3 [(xxii)] **(22)** phenazocine;
- 4 [(xxiii)] **(23)** piminodine;
- 5 [(xxiv)] **(24)** racemethorphan;
- 6 [(xxv)] **(25)** racemorphan;
- 7 [(xxvi)] **(26)** remifentanil;
- 8 [(xxvii)] **(27)** sulfentanil;
- 9 [(xxviii)] **(28)** tapentadol; and
- 10 [(xxix)] **(29)** thiafentanil.

11 [(2) Unless specifically excepted under this subtitle, an isomer, ester, ether,
 12 or salt of an opiate and a salt of an isomer, ester, or ether is a substance listed in Schedule
 13 II if the existence of the isomer, ester, ether, or salt is possible within the specific chemical
 14 designation.]

15 (d) **[A] UNLESS SPECIFICALLY EXCEPTED UNDER THIS SUBTITLE OR LISTED**
 16 **IN ANOTHER SCHEDULE, A** substance is listed in Schedule II if the substance includes a
 17 material, compound, mixture, or preparation that contains any quantity of the following
 18 substances having a potential for abuse associated with a stimulant effect on the central
 19 nervous system:

- 20 (1) amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 21 (2) **METHAMPHETAMINE, ITS SALTS, ISOMER, AND SALTS OF**
 22 **ISOMERS;**
- 23 (3) phenmetrazine and its salts;

24 [(3) a substance that contains any methamphetamine, including salts,
 25 optical isomers, and salts of its optical isomers, in combination with one or more active
 26 nonnarcotic ingredients in recognized therapeutic amounts;]

27 (4) methylphenidate; **AND**

28 (5) [methamphetamine, its salts, optical isomers, and salts of optical

1 isomers; and

2 (6) lisdexamfetamine, its salts, isomers, and salts of isomers.

3 (e) [(1) Unless specifically excepted under this subtitle or listed in another
4 schedule, a substance is listed in Schedule II if the substance includes a material,
5 compound, mixture, or preparation that contains any quantity of the following substances
6 having a depressant effect on the central nervous system, **INCLUDING ITS SALTS,
7 ISOMERS, AND SALTS OF ISOMERS WHENEVER THE EXISTENCE OF SUCH SALTS,
8 ISOMERS, AND SALTS OF ISOMERS IS POSSIBLE WITHIN THE SPECIFIC CHEMICAL
9 DESIGNATION:**

10 [(i) (1) amobarbital;

11 [(ii) (2) glutethimide;

12 [(iii) secobarbital;]

13 [(iv) (3) pentobarbital;

14 [(v) (4) phencyclidine; AND

15 [(vi) 1-(1-phenylcyclohexyl) piperidine;

16 (vii) 1-phenylcyclohexylamine; and

17 (viii) 1-piperidinocyclohexanecarbonitrile]

18 (5) **SECOBARBITAL.**

19 [(2) Unless specifically excepted under this subtitle or listed in another
20 schedule, a salt, isomer, or salt of an isomer of a substance listed in this subsection is
21 included in Schedule II if the existence of the salt, isomer, or salt of an isomer is possible
22 within the specific chemical designation.]

23 (F) **AS LISTED IN SCHEDULE II UNDER TITLE 21 OF THE CODE OF FEDERAL
24 REGULATIONS:**

25 (1) **NABILONE; AND**

26 (2) **DRONABINOL [(-)-DELTA-9-TRANS TETRAHYDROCANNABINOL]
27 IN AN ORAL SOLUTION IN A DRUG PRODUCT APPROVED FOR MARKETING BY THE
28 UNITED STATES FOOD AND DRUG ADMINISTRATION.**

29 (G) **UNLESS SPECIFICALLY EXCEPTED OR UNLESS LISTED IN ANOTHER**

1 SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION WHICH
2 CONTAINS ANY QUANTITY OF THE FOLLOWING SUBSTANCES:

3 (1) IMMEDIATE PRECURSOR TO AMPHETAMINE AND
4 METHAMPHETAMINE:

5 (I) PHENYLACETONE; AND

6 (II) RESERVED;

7 (2) IMMEDIATE PRECURSORS TO PHENCYCLIDINE (PCP):

8 (I) 1-PHENYLCYCLOHEXYLAMINE; AND

9 (II) 1-PIPERIDINOCYCLOHEXANECARBONITRILE (PCC); AND

10 (3) IMMEDIATE PRECURSOR TO FENTANYL:

11 (I) 4-ANILINO-N-PHENETHYLPIPERIDINE (ANPP); AND

12 (II) RESERVED.

13 [(f)] (H) The Department may not add a substance to Schedule II under § 5-202
14 of this title unless the Department finds:

15 (1) a high potential for abuse of the substance;

16 (2) currently accepted medical use of the substance in the United States,
17 or currently accepted medical use with severe restrictions; and

18 (3) evidence that abuse of the substance may lead to severe psychological
19 or physical dependence.

20 5-404.

21 (a) Schedule III consists of each controlled dangerous substance BY WHATEVER
22 OFFICIAL NAME, COMMON OR USUAL NAME, CHEMICAL NAME, OR BRAND NAME
23 DESIGNATED:

24 (1) listed in this section;

25 (2) added to Schedule III by the Department under § 5-202(b) of this title;
26 or

27 (3) designated as a Schedule III controlled dangerous substance by the

- 1 20. boldenone;
- 2 21. boldione;
- 3 22. calusterone;
- 4 23. chlorotestosterone;
- 5 24. clostebol;
- 6 25. dehydrochlormethyltestosterone;
- 7 26. desoxymethyltestosterone;
- 8 27. dihydrotestosterone;
- 9 28. drostanolone;
- 10 29. ethylestroenol;
- 11 30. fluoxymesterone;
- 12 31. formobulone;
- 13 32. furazabol;
- 14 33. mesterolone;
- 15 34. methandienone;
- 16 35. methandranone;
- 17 36. methandriol;
- 18 37. methandrostenolone;
- 19 38. methasterone;
- 20 39. methenolone;
- 21 40. methyldienolone;
- 22 41. methyltestosterone;
- 23 42. methyltrienolone;

- 1 43. mibolerone;
- 2 44. nandrolone;
- 3 45. norclostebol;
- 4 46. norethandrolone;
- 5 47. normethandrolone;
- 6 48. oxandrolone;
- 7 49. oxymesterone;
- 8 50. oxymetholone;
- 9 51. prostanazol;
- 10 52. stanolone;
- 11 53. stanozolol;
- 12 54. stenbolone;
- 13 55. testolactone;
- 14 56. testosterone;
- 15 57. tetrahydrogestrinone;
- 16 58. trenbolone; and
- 17 59. any isomer, ester, salt, or derivative of a substance listed
- 18 in this paragraph.

19 (2) The following substances are not included in Schedule III:

20 (i) an estrogen, progestin, or corticosteroid; or

21 (ii) a substance covered by paragraph (1) of this subsection if:

22 1. expressly intended for administration through implants to

23 cattle or other nonhuman species; and

24 2. approved for that use by the Food and Drug

25 Administration.]

1 **[(c)] (B)** (1) Unless **SPECIFICALLY EXCEPTED OR** listed in another
2 schedule, a substance is listed in Schedule III if the substance includes a material,
3 compound, mixture, or preparation that contains any quantity of the following substances
4 having a stimulant effect on the central nervous system:

5 (i) **THOSE COMPOUNDS, MIXTURES, OR PREPARATIONS IN**
6 **DOSAGE UNIT FORM CONTAINING ANY STIMULANT SUBSTANCES LISTED IN**
7 **SCHEDULE II, WHICH COMPOUNDS, MIXTURES, OR PREPARATIONS WERE LISTED ON**
8 **AUGUST 25, 1971, AS EXCEPTED COMPOUNDS UNDER § 1308.32 OF THE CODE OF**
9 **FEDERAL REGULATIONS, AND ANY OTHER DRUG OF THE QUANTITATIVE**
10 **COMPOSITION SHOWN IN THAT LIST FOR THOSE DRUGS OR THAT IS THE SAME**
11 **EXCEPT THAT IT CONTAINS A LESSER QUANTITY OF CONTROLLED SUBSTANCES;**

12 (II) benzphetamine;

13 **[(ii)] (III)** chlorphentermine;

14 **[(iii)] (IV)** clortermine;

15 **[(iv)** mazindol;] and

16 (v) phendimetrazine.

17 (2) Subject to paragraph (3) of this subsection, substances in Schedule III
18 include:

19 (i) a salt of a substance listed in this subsection;

20 (ii) an optical, position, or geometric isomer of a substance listed in
21 this subsection; or

22 (iii) a salt of an isomer of a substance listed in this subsection.

23 (3) Unless listed in another schedule, a salt, isomer, or salt of an isomer
24 described in paragraph (2) of this subsection may be included in Schedule III only if the
25 existence of the salts, isomers, and salts of isomers is possible within the specific chemical
26 designation.

27 **[(d)] (C)** Unless listed in another schedule, a substance is listed in Schedule III
28 if the substance includes a material, compound, mixture, or preparation that contains any
29 quantity of the following substances having a potential for abuse associated with a
30 depressant effect on the central nervous system:

31 (1) **ANY COMPOUND, MIXTURE, OR PREPARATION CONTAINING:**

32 (I) **AMOBARBITAL;**

1 (II) SECOBARBITAL;

2 (III) PENTOBARBITAL; OR

3 (IV) ANY SALT THEREOF AND ONE OR MORE OTHER ACTIVE
4 MEDICINAL INGREDIENTS THAT ARE NOT LISTED IN ANY SCHEDULE;

5 (2) ANY SUPPOSITORY DOSAGE FORM CONTAINING:

6 (I) AMOBARBITAL;

7 (II) SECOBARBITAL;

8 (III) PENTOBARBITAL; OR

9 (IV) ANY SALT OF ANY OF THESE DRUGS AND APPROVED BY THE
10 U.S. FOOD AND DRUG ADMINISTRATION FOR MARKETING ONLY AS A SUPPOSITORY;

11 [(1)] (3) except those substances that are specifically listed in other
12 schedules, a substance that contains any quantity of a derivative of barbituric acid, [or] a
13 salt of a derivative of a barbituric [acid];

14 (2) aprobarbital;

15 (3) butabarbital (secbutabarbital);

16 [(4)] ACID, OR butalbital [(fiorinal)], INCLUDING, WITH ONE OR MORE
17 ACTIVE, NONNARCOTIC INGREDIENTS IN RECOGNIZED THERAPEUTIC AMOUNTS,
18 (FIORICET) AND (FIORINAL);

19 [(5) butobarbital (butethal);]

20 [(6)] (4) chlorhexadol;

21 [(7)] (5) embutramide;

22 [(8) gamma hydroxybutyric acid preparations;]

23 (6) ANY DRUG PRODUCT CONTAINING GAMMA HYDROXYBUTYRIC
24 ACID, INCLUDING ITS SALTS, ISOMERS, AND SALTS OF ISOMERS, FOR WHICH AN
25 APPLICATION IS APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG,
26 AND COSMETIC ACT;

1 **(7) KETAMINE, ITS SALTS, ISOMERS, AND SALTS OF ISOMERS;**

2 **[(9) (8) lysergic acid;**

3 **[(10) (9) lysergic acid amide;**

4 **[(11) (10) methyprylon;**

5 **[(12) pentazocine;]**

6 **[(13) (11) perampanel, AND ITS SALTS, ISOMERS, AND SALTS OF**
7 **ISOMERS (FYCOMPA);**

8 **[(14) (12) sulfondiethylmethane;**

9 **[(15) (13) sulfonethylmethane;**

10 **[(16) (14) sulfonmethane; AND**

11 **[(17) talbutal;**

12 **(18) thiamylal;**

13 **(19) thiopental; and**

14 **(20) vinbarbital.]**

15 **(15) TILETAMINE AND ZOLAZEPAM OR ANY SALT THEREOF, INCLUDING**
16 **A TILETAMINE–ZOLAZEPAM COMBINATION PRODUCT (TRADE NAME TELAZOL).**

17 **(D) AS LISTED IN SCHEDULE III UNDER TITLE 21 OF THE CODE OF**
18 **FEDERAL REGULATIONS, NALORPHINE 9400.**

19 **(e) UNLESS SPECIFICALLY EXCEPTED OR UNLESS LISTED IN ANOTHER**
20 **SCHEDULE:**

21 **(1) [Substances] SUBSTANCES listed in Schedule III include [a] ANY**
22 **material, compound, mixture, or preparation [that contains limited quantities of any of**
23 **these narcotic drugs or their salts] CONTAINING ANY OF THE FOLLOWING NARCOTIC**
24 **DRUGS, OR THEIR SALTS CALCULATED AS THE FREE ANHYDROUS BASE OR**
25 **ALKALOID, IN LIMITED QUANTITIES AS SET FORTH BELOW:**

26 **(i) not more than 1.80 grams of codeine per 100 milliliters or not**
27 **more than 90 milligrams per dosage unit, with an equal or greater quantity of an**
28 **isoquinoline alkaloid of opium;**

1 (ii) not more than 1.80 grams of codeine per 100 milliliters or not
2 more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients
3 in recognized therapeutic amounts;

4 (iii) [not more than 300 milligrams of dihydrocodeinone per 100
5 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater
6 quantity of an isoquinoline alkaloid of opium;

7 (iv) not more than 300 milligrams of dihydrocodeinone per 100
8 milliliters or not more than 15 milligrams per dosage unit, with one or more active,
9 nonnarcotic ingredients in recognized therapeutic amounts;

10 (v)] not more than 1.80 grams of dihydrocodeine per 100 milliliters
11 or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic
12 ingredients in recognized therapeutic amounts;

13 [(vi)] (IV) not more than 300 milligrams of ethylmorphine per 100
14 milliliters or not more than 15 milligrams per dosage unit, with one or more active,
15 nonnarcotic ingredients in recognized therapeutic amounts;

16 [(vii)] (V) not more than 500 milligrams of opium per 100 milliliters
17 or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active,
18 nonnarcotic ingredients in recognized therapeutic amounts;

19 [(viii)] (VI) not more than 100 milligrams of opium per 100 milliliters
20 or per 100 grams, or not more than 5 milligrams per dosage unit; AND

21 [(ix)] (VII) not more than 50 milligrams of morphine per 100
22 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized
23 therapeutic amounts[; and

24 (x) buprenorphine].

25 [(2) Substances listed in Schedule III include a compound, mixture, or
26 preparation or salt of a compound, mixture, or preparation and another active medicinal
27 ingredient that is not listed in another schedule and that contains:

28 (i) amobarbital;

29 (ii) secobarbital; or

30 (iii) pentobarbital.]

31 (2) ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION
32 CONTAINING ANY OF THE FOLLOWING NARCOTIC DRUGS OR THEIR SALTS, AS SET

1 FORTH BELOW:

2 (I) BUPRENORPHINE; AND

3 (II) RESERVED.

4 (3) [If] IF not combined with one or more active medicinal ingredients that
5 are listed in another schedule, substances listed in Schedule III include a suppository
6 dosage form or salt of a suppository dosage that contains:

7 (i) amobarbital;

8 (ii) secobarbital; or

9 (iii) pentobarbital.

10 (f) (1) EXCEPT AS PROVIDED IN PARAGRAPH (2) OF THIS SUBSECTION,
11 AN ANABOLIC STEROID CONSISTING OF ANY MATERIAL, COMPOUND, MIXTURE, OR
12 PREPARATION CONTAINING ANY QUANTITY OF THE FOLLOWING SUBSTANCES,
13 INCLUDING ITS SALTS, ESTERS, AND ETHERS:

14 (I) 3BETA,17-DIHYDROXY-5A-ANDROSTANE;

15 (II) 3ALPHA,17BETA-DIHYDROXY-5A-ANDROSTANE;

16 (III) 5 ALPHA-ANDROSTAN-3,17-DIONE;

17 (IV) 1-ANDROSTENEDIOL
18 (3BETA,17BETA-DIHYDROXY-5ALPHA-ANDROST-1-ENE);

19 (V) 1-ANDROSTENEDIOL
20 (3ALPHA,17BETA-DIHYDROXY-5ALPHA-ANDROST-1-ENE);

21 (VI) 4-ANDROSTENEDIOL
22 (3BETA,17BETA-DIHYDROXY-ANDROST-4-ENE);

23 (VII) 5-ANDROSTENEDIOL
24 (3BETA,17BETA-DIHYDROXY-ANDROST-5-ENE);

25 (VIII) 1-ANDROSTENEDIONE;

26 (IX) 4-ANDROSTENEDIONE;

27 (X) 5-ANDROSTENEDIONE;

- 1 (XI) BOLASTERONE;
- 2 (XII) BOLDENONE;
- 3 (XIII) BOLDIONE;
- 4 (XIV) CALUSTERONE;
- 5 (XV) CHLOROTESTOSTERONE (CLOBOL);
- 6 (XVI) DEHYDROCHLOROMETHYLTESTOSTERONE;
- 7 (XVII) DESOXYMETHYLTESTOSTERONE;
- 8 (XVIII) DELTA1-DIHYDROTESTOSTERONE
9 (17BETA-HYDROXY-5ALPHA-ANDROST-1-EN-3-ONE);
- 10 (XIX) DIHYDROTESTOSTERONE (4-DIHYDROTESTOSTERONE)
11 (17BETA-HYDROXY-ANDROSTAN-3-ONE) (STANOLONE);
- 12 (XX) DROSTANOLONE;
- 13 (XXI) ETHYLESTRENOL;
- 14 (XXII) FLUOXYMESTERONE;
- 15 (XXIII) FORMEBOLONE;
- 16 (XXIV) FURAZABOL;
- 17 (XXV) 13BETA-ETHYL-17BETA-HYDROXYGON-4-EN-3-ONE;
- 18 (XXVI) 4-HYDROXYTESTOSTERONE;
- 19 (XXVII) 4-HYDROXY-19-NORTESTOSTERONE;
- 20 (XXVIII) MESTANOLONE
21 (17ALPHA-METHYL-17BETA-HYDROXY-5-ANDROSTAN-3-ONE);
- 22 (XXIX) MESTEROLONE;

- 1 (XXX) METHANDIENONE (METHANDROSTENOLONE)
2 (17ALPHA-METHYL-17BETA-HYDROXYANDROST-1,4-DIEN-3-ONE);
- 3 (XXXI) METHANDRIOL;
- 4 (XXXII) METHASTERONE;
- 5 (XXXIII) METHENOLONE;
- 6 (XXXIV) 17ALPHA-METHYL-3BETA,
7 17BETA-DIHYDROXY-5A-ANDROSTANE;
- 8 (XXXV) 17ALPHA-METHYL-3ALPHA,
9 17BETA-DIHYDROXY-5A-ANDROSTANE;
- 10 (XXXVI) 17ALPHA-METHYL-3BETA,
11 17BETA-DIHYDROXYANDROST-4-ENE;
- 12 (XXXVII) 17ALPHA-METHYL-4-HYDROXYNANDROLONE;
- 13 (XXXVIII) METHYLDIENOLONE;
- 14 (XXXIX) METHYLTRIENOLONE;
- 15 (XL) METHYLTESTOSTERONE;
- 16 (XLI) MIBOLERONE;
- 17 (XLII) 17ALPHA-METHYL-DELTA1-DIHYDROTESTOSTERONE;
- 18 (XLIII) NANDROLONE;
- 19 (XLIV) 19-NOR-4-ANDROSTENEDIOL (3BETA,
20 17BETA-DIHYDROXYESTR-4-ENE);
- 21 (XLV) 19-NOR-4-ANDROSTENEDIOL (3ALPHA,
22 17BETA-DIHYDROXYESTR-4-ENE);
- 23 (XLVI) 19-NOR-5-ANDROSTENEDIOL (3BETA,
24 17BETA-DIHYDROXYESTR-5-ENE);
- 25 (XLVII) 19-NOR-5-ANDROSTENEDIOL (3ALPHA,
26 17BETA-DIHYDROXYESTR-5-ENE);

- 1 (XLVIII) 19-NOR-4,9(10)-ANDROSTADIENEDIONE;
- 2 (XLIX) 19-NOR-4-ANDROSTENEDIONE;
- 3 (L) 19-NOR-5-ANDROSTENEDIONE;
- 4 (LI) NORBOLETHONE (13BETA,
5 17ALPHA-DIETHYL-17BETA-HYDROXYGON-4-EN-3-ONE);
- 6 (LII) NORCLOSTEBOL;
- 7 (LIII) NORETHANDROLONE;
- 8 (LIV) NORMETHANDROLONE;
- 9 (LV) OXANDROLONE;
- 10 (LVI) OXYMESTERONE;
- 11 (LVII) OXYMETHOLONE;
- 12 (LVIII) PROSTANOZOL;
- 13 (LIX) STANZOLOL;
- 14 (LX) STENBOLONE;
- 15 (LXI) TESTOLACTONE;
- 16 (LXII) TESTOSTERONE;
- 17 (LXIII) TETRAHYDROGESTRINONE; AND
- 18 (LXIV) TRENBOLONE.

19 (2) THE FOLLOWING SUBSTANCES ARE NOT INCLUDED IN SCHEDULE
20 III:

- 21 (I) AN ESTROGEN, PROGESTIN, OR CORTICOSTEROID; OR
- 22 (II) A SUBSTANCE COVERED BY PARAGRAPH (1) OF THIS
23 SUBSECTION IF:

1 **1. EXPRESSLY INTENDED FOR ADMINISTRATION**
2 **THROUGH IMPLANTS TO CATTLE OR OTHER NONHUMAN SPECIES; AND**

3 **2. APPROVED FOR THAT USE BY THE U.S. FOOD AND**
4 **DRUG ADMINISTRATION.**

5 **(G)** [Substances listed in Schedule III] **HALLUCINOGENIC SUBSTANCES**
6 include:

7 (1) dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin
8 capsule in a U.S. Food and Drug Administration–approved product; **AND**

9 (2) [ketamine, its salts, isomers, and salts of isomers; and

10 (3) fioricet (containing butalbital, acetaminophen, and caffeine)]

11 **RESERVED.**

12 **[(g)] (H)** The Department may not add a substance to Schedule III under §
13 5–202 of this title unless the Department finds:

14 (1) a potential for abuse of the substance that is less than that for the
15 substances listed in Schedule I and Schedule II;

16 (2) well documented and approved medical use of the substance in the
17 United States; and

18 (3) evidence that abuse of the substance may lead to moderate or low
19 physical dependence or high psychological dependence.

20 5–405.

21 (a) Schedule IV consists of each controlled dangerous substance:

22 (1) listed in this section;

23 (2) added to Schedule IV by the Department under § 5–202(b) of this title;

24 or

25 (3) designated as a Schedule IV controlled dangerous substance by the
26 federal government unless the Department objects under § 5–202(f) of this title.

27 **(b) UNLESS SPECIFICALLY EXCEPTED OR UNLESS LISTED IN ANOTHER**
28 **SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION CONTAINING**
29 **ANY OF THE FOLLOWING NARCOTIC DRUGS, OR THEIR SALTS CALCULATED AS THE**
30 **FREE ANHYDROUS BASE OR ALKALOID, IN LIMITED QUANTITIES AS SET FORTH**

1 **BELOW:**

2 **(1) NOT MORE THAN 1 MILLIGRAM OF DIFENOXIN AND NOT LESS THAN**
3 **25 MICROGRAMS OF ATROPINE SULFATE PER DOSAGE UNIT;**

4 **(2) DEXTROPROPOXYPHENE (ALPHA-(+)-4-DIMETHYLAMINO-1,**
5 **2-DIPHENYL-3-METHYL-2-PROPIONOXYBUTANE); AND**

6 **(3) 2-[(DIMETHYLAMINO)METHYL]-1-(3-**
7 **METHOXYPHENYL)CYCLOHEXANOL, ITS SALTS, OPTICAL AND GEOMETRIC ISOMERS**
8 **AND SALTS OF THESE ISOMERS (INCLUDING TRAMADOL).**

9 **(C) Substances listed in Schedule IV include a material, compound, mixture, or**
10 **preparation that contains any quantity of the following substances having a potential for**
11 **abuse associated with a depressant effect on the central nervous system, INCLUDING ITS**
12 **SALTS, ISOMERS, AND SALTS OF ISOMERS WHENEVER THE EXISTENCE OF SUCH**
13 **SALTS, ISOMERS, AND SALTS OF ISOMERS IS POSSIBLE WITHIN THE SPECIFIC**
14 **CHEMICAL DESIGNATIONS:**

15 (1) alfaxalone;

16 (2) alprazolam;

17 (3) barbital;

18 (4) **BREXANOLONE;**

19 **(5) bromazepam;**

20 **[(5) butorphanol;]**

21 (6) camazepam;

22 (7) carisoprodol;

23 (8) [cathine +/- (norpseudoepedrine);

24 (9)] chloral betaine;

25 **[(10) (9) chloral hydrate;**

26 **[(11) (10) chlordiazepoxide;**

27 **[(12) (11) clobazam;**

- 1 [(13)] **(12)** clonazepam;
- 2 [(14)] **(13)** clorazepate;
- 3 [(15)] **(14)** clotiazepam;
- 4 [(16)] **(15)** cloxazolam;
- 5 [(17)] **(16)** delorazepam;
- 6 [(18) dexfenfluramine;
- 7 (19) dextropropoxyphene dosage forms;
- 8 (20)] **(17)** diazepam;
- 9 [(21)] **(18)** dichloralphenazone;
- 10 [(22) eluxadoline (viberzi);
- 11 (23)] **(19)** estazolam;
- 12 [(24)] **(20)** ethchlorvynol;
- 13 [(25)] **(21)** ethinamate;
- 14 [(26)] **(22)** [ethylloflazepate] **ETHYL LOFLAZEPATE;**
- 15 [(27) fencamfamin;
- 16 (28) fenproporex;]
- 17 [(29)] **(23)** fludiazepam;
- 18 [(30)] **(24)** flunitrazepam;
- 19 [(31)] **(25)** flurazepam;
- 20 **(26) FOSPROPOFOL;**
- 21 [(32)] **(27)** halazepam;
- 22 [(33)] **(28)** haloxazolam;
- 23 [(34)] **(29)** ketazolam;

- 1 [(35) (30) loprazolam;
- 2 [(36) (31) lorazepam;
- 3 [(37) (32) lormetazepam;
- 4 [(38) (33) mebutamate;
- 5 [(39) (34) medazepam;
- 6 [(40) mefenorex;]
- 7 [(41) (35) [methohexital] MEPROBAMATE;
- 8 [(42) (36) [meprobamate] METHOHEXITAL;
- 9 [(43) (37) methylphenobarbital (MEPHOBARBITAL);
- 10 [(44) (38) midazolam;
- 11 [(45) modafinil;]
- 12 [(46) (39) nimetazepam;
- 13 [(47) (40) [nitrozepam] NITRAZEPAM;
- 14 [(48) (41) nordiazepam;
- 15 [(49) (42) oxazepam;
- 16 [(50) (43) oxazolam;
- 17 [(51) (44) paraldehyde;
- 18 [(52) (45) petrichloral;
- 19 [(53) (46) phenobarbital;
- 20 [(54) (47) pinazepam;
- 21 [(55) pipradrol;]
- 22 [(56) (48) prazepam;

1 (II) AN OPTICAL, POSITION, OR GEOMETRIC ISOMER OF
2 LORCASERIN; AND

3 (III) A SALT OF AN ISOMER OF LORCASERIN.

4 [(d)] (F) Substances listed in Schedule IV include a material, compound,
5 mixture, or preparation that contains any quantity of the following substances having a
6 potential for abuse associated with a stimulant effect on the central nervous system,
7 INCLUDING ITS SALTS, ISOMERS, AND SALTS OF ISOMERS:

8 (1) CATHINE ((+)-NORPSEUDOEPHEDRINE);

9 (2) diethylpropion;

10 (3) FENCAMFAMIN;

11 (4) FENPROPOREX;

12 (5) MAZINDOL;

13 (6) MEFENOREX;

14 (7) MODAFINIL;

15 [(2)] (8) pemoline, including organometallic complexes and their
16 chelates; [and]

17 [(3)] (9) phentermine;

18 (10) PIPRADROL;

19 (11) SIBUTRAMINE;

20 (12) SOLRIAMFETOL (2-AMINO-3-PHENYLPROPYL CARBAMATE;
21 BENZENEPROPANOL, BETA-AMINO-, CARBAMATE (ESTER)); AND

22 (13) SPA ((-)-1-DIMETHYLAMINO- 1,2-DIPHENYLETHANE).

23 (G) UNLESS SPECIFICALLY EXCEPTED OR UNLESS LISTED IN ANOTHER
24 SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION THAT
25 CONTAINS ANY QUANTITY OF THE FOLLOWING SUBSTANCES, INCLUDING ITS SALTS:

26 (1) PENTAZOCINE;

1 (2) BUTORPHANOL (INCLUDING ITS OPTICAL ISOMERS); AND

2 (3) ELUXADOLINE (5-[[[(2S)-2-AMINO-3-[4-AMINOCARBONYL)-2,
3 6-DIMETHYLPHENYL]-1-OXOPROPYL]](1S)-1-(4-PHENYL-1H-IMIDAZOL-2-
4 YL)ETHYL]AMINO]METHYL]-2-METHOXYBENZOIC ACID) (INCLUDING ITS OPTICAL
5 ISOMERS) AND ITS SALTS, ISOMERS, AND SALTS OF ISOMERS.

6 [(e) (H) By regulation, the Department may exempt from this section a
7 compound, mixture, or preparation that contains a depressant substance listed in
8 subsection (b) of this section if:

9 (1) the compound, mixture, or preparation contains an active medicinal
10 ingredient that does not have a depressant effect on the central nervous system; and

11 (2) the admixtures are included in combinations, quantity, proportion, or
12 concentration that vitiate the potential for abuse of the substances that have a depressant
13 effect on the central nervous system.

14 [(f) (I) The Department may not add a substance to Schedule IV under §
15 5-202 of this title unless the Department finds that:

16 (1) the substance has a low potential for abuse relative to the substances
17 listed in Schedule III;

18 (2) the substance has currently accepted medical use in treatment in the
19 United States; and

20 (3) abuse of the substance may lead to limited physical dependence or
21 psychological dependence relative to the substances in Schedule III.

22 5-406.

23 (a) Schedule V consists of each controlled dangerous substance:

24 (1) listed in this section;

25 (2) added to Schedule V by the Department under § 5-202(b) of this title;
26 or

27 (3) designated as a Schedule V controlled dangerous substance by the
28 federal government unless the Department objects under § 5-202(f) of this title.

29 (b) [A substance is listed in Schedule V if the substance includes a compound,
30 mixture, or preparation that contains the following narcotic drugs or their salts] **UNLESS**
31 **SPECIFICALLY EXCEPTED OR UNLESS LISTED IN ANOTHER SCHEDULE, ANY**
32 **MATERIAL, COMPOUND, MIXTURE, OR PREPARATION CONTAINING ANY OF THE**

1 FOLLOWING NARCOTIC DRUGS AND THEIR SALTS, AS SET FORTH BELOW:

2 (1) RESERVED; AND

3 (2) RESERVED.

4 (C) ANY COMPOUND, MIXTURE, OR PREPARATION CONTAINING ANY OF THE
 5 FOLLOWING NARCOTIC DRUGS, OR THEIR SALTS CALCULATED AS THE FREE
 6 ANHYDROUS BASE OR ALKALOID, IN LIMITED QUANTITIES AS SET FORTH BELOW,
 7 WHICH SHALL INCLUDE ONE OR MORE NONNARCOTIC ACTIVE MEDICINAL
 8 INGREDIENTS IN SUFFICIENT PROPORTION TO CONFER UPON THE COMPOUND,
 9 MIXTURE, OR PREPARATION VALUABLE MEDICINAL QUALITIES OTHER THAN THOSE
 10 POSSESSED BY NARCOTIC DRUGS ALONE:

11 (1) [(i)] not more than 200 milligrams of codeine per 100 milliliters or per
 12 100 grams;

13 [(ii)] (2) not more than 100 milligrams of dihydrocodeine per 100
 14 milliliters or per 100 grams;

15 [(iii)] (3) not more than [50] 100 milligrams of ethylmorphine per
 16 100 milliliters or per 100 grams;

17 [(iv)] (4) not more than 2.5 milligrams of diphenoxylate and not less
 18 than 25 micrograms of atropine sulfate per dosage unit; OR

19 [(v) brivaracetam;]

20 [(vi)] (5) difenoxin preparations 0.5mg/25ug ATSO4/DU
 21 (MOTOFEN)[;

22 (vii) ezogabine (potiga);

23 (viii) lacosamide (vimpat);

24 (ix) pregabalin (lyrica); or

25 (x) pyrovalerone; and

26 (2) nonnarcotic active medicinal ingredients in sufficient proportion to
 27 confer on the compound, mixture, or preparation valuable medicinal qualities other than
 28 those possessed by the narcotic drug alone].

29 (D) UNLESS SPECIFICALLY EXEMPTED OR EXCLUDED OR UNLESS LISTED IN
 30 ANOTHER SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION

1 THAT CONTAINS ANY QUANTITY OF THE FOLLOWING SUBSTANCES HAVING A
2 STIMULANT EFFECT ON THE CENTRAL NERVOUS SYSTEM, INCLUDING ITS SALTS,
3 ISOMERS, AND SALTS OF ISOMERS:

4 (1) PYROVALERONE; AND

5 (2) RESERVED.

6 (E) UNLESS SPECIFICALLY EXEMPTED OR EXCLUDED OR UNLESS LISTED IN
7 ANOTHER SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION
8 THAT CONTAINS ANY QUANTITY OF THE FOLLOWING SUBSTANCES HAVING A
9 DEPRESSANT EFFECT ON THE CENTRAL NERVOUS SYSTEM, INCLUDING ITS SALTS:

10 (1) BRIVARACETAM
11 ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (BRIVIACT);

12 (2) EZOGABINE
13 [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl
14 ester] (POTIGA);

15 (3) LACOSAMIDE
16 [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide] (VIMPAT); AND

17 (4) PREGABALIN [(S)-3-(aminomethyl)-5-methylhexanoic
18 acid] (LYRICA).

19 (F) A DRUG PRODUCT IN FINISHED DOSAGE FORMULATION THAT HAS BEEN
20 APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION THAT
21 CONTAINS CANNABIDIOL (2-[1R-3-methyl-6R-(1-methylethenyl)-2-
22 cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) DERIVED FROM CANNABIS AND
23 NO MORE THAN 0.1% (W/W) RESIDUAL TETRAHYDROCANNABINOLS.

24 [(c)] (G) The Department may not add a substance to Schedule V under § 5-202
25 of this title unless the Department finds:

26 (1) the substance has a low potential for abuse relative to the substances
27 listed in Schedule IV;

28 (2) the substance has currently accepted medical use in the United States;
29 and

30 (3) abuse of the substance may lead to limited physical dependence or
31 psychological dependence liability relative to the substances listed in Schedule IV.

1 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
2 October 1, 2020.

Approved:

Governor.

Speaker of the House of Delegates.

President of the Senate.